The NIHR have recently published an article on the STAMPEDE trial which is helping to improve the prognosis and quality of life of those diagnosed with prostate cancer.
This is a research study that’s supported by the NIHR, and has been up and running since 2005, with more than 10,000 men having taken part. 125 UK sites are conducting the research, with local NHS Trusts amongst those 125.
The trial is multi-arm, so compares different treatments amongst the participant group – it is also ‘randomised’, so participants are allocated their treatment at random, reducing any bias in allocation.
The results to date from the trial have also influenced the NHS treatment for men with high risk, locally advanced metastatic prostate cancer. More STAMPEDE related news can be found on their website.
You can read the article here, which contains a testimony from a trial participant whose condition and quality of life have been vastly improved.